Navigation Links
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
Date:3/22/2011

TUESDAY, March 22 (HealthDay News) -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.

Italian researchers collected data on 832 patients who were taking Gleevec (imatinib) for up to eight years and found that 20 patients died during the follow-up period. That death rate of 4.8 percent, however, is similar to what would be expected in the general population.

Only six deaths were related to chronic myeloid leukemia (CML), the researchers noted.

Serious adverse events such as cardiovascular and digestive problems were reported in 139 patents, but only 27 cases (19 percent) were considered to be related to Gleevec, according to the study.

Other adverse events frequently connected to Gleevec included muscle cramps, weakness, edema, skin fragility, diarrhea, and tendon or ligament lesions. Nineteen patients (2.3 percent) stopped taking Gleevec due to side effects, with half switching to another drug.

Patients taking Gleevec "frequently suffer from side effects that are non-serious but can nonetheless reduce their quality of life," the researchers wrote.

The study authors disclosed no conflicts of interest, noting that their independence from pharmaceutical interests was a major strength of the study.

The researchers also noted the "importance of a good patient-provider relationship, in which side effects are easily communicated and addressed to reduce/avoid non-compliance."

In an accompanying editorial, Dr. B. Douglas Smith of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, noted "the astounding effect [imatinib] has had on the clinical course of this disease."

However, he wrote that many patients in the study had been treated first with interferon, which may have been a factor in their remissions. For this reason, he concluded, "a careful analysis of the two groups" -- patients who had taken interferon and those who had not -- "might help shed light on this issue."

The study appears online March 22 in the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about chronic myeloid leukemia.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, March 22, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Less Is More With Acute Myeloid Leukemia Drug
2. When leukemia returns, gene that mediates response to key drug often mutated
3. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
4. Scientists bioengineer a protein to fight leukemia
5. Southampton scientists begin patient trials of new leukemia cancer vaccine
6. Discovery of a gene associated with a leukemia mostly affecting children
7. MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia
8. Gene Activity May Affect Acute Myeloid Leukemia Outcome
9. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
10. Researchers make critical leukemia stem cell discovery
11. New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: